Mechanism of action of glatiramer acetate in treatment of multiple sclerosis |
| |
Authors: | Martin S Weber Reinhard Hohlfeld Scott S Zamvil |
| |
Institution: | (1) The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel |
| |
Abstract: | Glatiramer acetate (GA) (Copolymer-1, Copaxone, Teva, Israel, YEAK) is a polypeptide-based therapy approved for the treatment
of relapsing-remitting multiple sclerosis. Most investigations have attributed the immunomodulatory effect of GAs to its capability
to alter T-cell differentiation. Specifically, GA treatment is believed to promote development of Th2-polarized GA-reactive
CD4+ T-cells, which may dampen neighboring inflammation within the central nervous system. Recent reports indicate that the deficiency
in CD4+CD25+FoxP3+ regulatory T-cells in multiple sclerosis is restored by GA treatment. GA also exerts immunomodulatory activity on antigen
presenting cells, which participate in innate immune responses. These new findings represent a plausible explanation for GA-mediated
T-cell immune modulation and may provide useful insight for the development of new and more effective treatment options for
multiple sclerosis. |
| |
Keywords: | |
本文献已被 ScienceDirect SpringerLink 等数据库收录! |
|